FSH immunoneutralization acutely impairs spermatogonial development in normal adult rats.
Follicle-stimulating hormone (FSH) plays an important part in testicular development. Its role in the regulation of spermatogenesis in the adult, however, remains controversial. This study aimed to explore the role of FSH in the maintenance of adult rat spermatogenesis by using immunoneutralization to selectively withdraw FSH action for periods of up to 8.5 days and then assessing the outcome by quantification of germ cell number. Adult rats received either an ovine polyclonal rat FSH antibody (FSHAb, 2 mg/kg subcutaneous daily-a dosage known to neutralize >90% of FSH in serum) for 2, 4, 7, or 8.5 days or a control sheep immunoglobulin (ConAb, 2 mg/kg) for 8.5 days. Testes were perfusion fixed, and germ cell numbers per testis were quantified using the optical disector (sic) stereological method. The percentage of seminiferous tubules displaying apoptotic cells was determined by the in situ end labeling method (TUNEL). FSHAb treatment for 4, 7, or 8.5 days significantly reduced the number of type A/intermediate spermatogonia (approximately 74% of control values) associated with stages I-IV. Similar reductions were seen in type B spermatogonial and preleptotene spermatocyte numbers after 8.5 days of FSHAb treatment (approximately 69% of control values; P < 0.05). Decreases (P < 0.05) in the numbers of pachytene spermatocytes in stages I-III and VIII, round spermatids in stages I-III, VII, and VIII (approximately 70% of control values), and step 19 elongated spermatids in stage VII (51% of control values) were achieved after 8.5 days of FSHAb treatment. Compared with control, FSHAb treatment increased the percentage of stage XIV-III tubules containing TUNEL-positive cells by about twofold after 7 days of FSHAb treatment (P < 0.05). This study supports a role for FSH in the maintenance of quantitatively normal adult rat spermatogenesis, specifically by regulating A3 and A4 spermatogonial subtypes. FSH may act on these spermatogonia by enhancing the stage-dependent survival of type A spermatogonia. Effects at other sites in spermatogenesis are suggested by the changes in spermatocyte and spermatid populations. However, to clarify these effects, selective FSH withdrawal would need to be prolonged until steady state had been achieved.
Meachem
S J
SJ
Prince Henry's Institute of Medical Research, Monash Medical Centre, Clayton, Victoria, Australia.
Mclachlan
R I
RI
Stanton
P G
PG
Robertson
D M
DM
Wreford
N G
NG
D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D017209:Apoptosis; D005640:Follicle Stimulating Hormone / Q000037:antagonists & inhibitors / Q000276:immunology / Q000502:physiology*; D007116:Immunization, Passive; D020287:In Situ Nick-End Labeling; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D012756:Sheep; D013090:Spermatocytes / Q000166:cytology / Q000502:physiology; D013093:Spermatogonia / Q000166:cytology / Q000502:physiology*; D013737:Testis / Q000166:cytology / Q000502:physiology*
D000906:Antibodies; D005640:Follicle Stimulating Hormone